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Abstract 
Constitutive regulation by PKA has recently been shown to contribute to L-type Ca2+ current 
(ICaL) at the ventricular t-tubule in heart failure. Conversely, reduction in constitutive 
regulation by PKA has been proposed to underlie the downregulation of atrial ICaL in heart 
failure. The hypothesis that downregulation of atrial ICaL in heart failure involves reduced 
channel phosphorylation was examined. Anesthetized adult male Wistar rats underwent 
surgical coronary artery ligation (CAL, N=10) or equivalent sham-operation (Sham, N=12).   
Left atrial myocytes were isolated ~18 weeks post-surgery and whole-cell currents recorded 
(holding potential=-80 mV).  ICaL activated by depolarizing pulses to voltages from -40 to +50 
mV were normalized to cell capacitance and current density-voltage relations plotted.  CAL 
cell capacitances were ~1.67-fold greater than Sham (P≤0.0001). Maximal ICaL conductance 
(Gmax) was downregulated more than 2-fold in CAL vs Sham myocytes (P<0.0001).  
Norepinephrine (1 μmol/L) increased Gmax >50% more effectively in CAL than in Sham so 
that differences in ICaL density were abolished. Differences between CAL and Sham Gmax 
were not abolished by calyculin A (100 nmol/L) , suggesting that increased protein 
dephosphorylation did not account for ICaL downregulation. Treatment with either H-89 (10 
μmol/L) or AIP (5 μmol/L) had no effect on basal currents in Sham or CAL myocytes, 
indicating that, in contrast to ventricular myocytes, neither PKA nor CaMKII regulated basal 
ICaL.  Expression of the L-type 1C-subunit, protein phosphatases 1 and 2A and inhibitor-1 
proteins was unchanged. In conclusion, reduction in PKA-dependent regulation did not 
contribute to downregulation of atrial ICaL in heart failure.  
 
Key words:      atrial remodeling, coronary artery ligation, voltage-gated Ca2+ channel
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New and Noteworthy Statement 
Whole-cell recording of L-type Ca2+ currents in atrial myocytes from rat hearts subjected to 
coronary artery ligation in comparison with those from sham-operated controls reveals 
marked reduction in current density in heart failure without change in channel subunit 
expression and associated with altered phosphorylation independent of protein kinase A. 
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Introduction 
Atrial fibrillation (AF) is the most common clinical arrhythmia and is associated with 
significant mortality, primarily through stroke and heart failure (2, 3).  There are many 
causes of AF and although patients generally show multiple predisposing risk factors, >70% 
of patients have some form of underlying structural heart disease (2, 3).  Evidence from 
animal models of heart diseases that predispose to AF indicates that disease-associated 
remodeling of the atria, presumably due to mechanical overload of the atrial wall, creates 
an arrhythmic substrate in which AF is more likely to arise and be sustained (10, 13, 22, 29, 
30, 32, 34, 48). In addition to atrial enlargement, fibrosis and conduction abnormalities that 
establish a substrate for re-entry, cellular remodeling involving cellular hypertrophy, 
changes in membrane structure and abnormal expression and function of ion channels and 
transporters are also likely to contribute to the genesis of AF (4, 10, 13, 15, 16, 18, 22, 26, 
29, 30, 32, 34, 35, 38, 48, 51).   
Atrial L-type Ca2+ current (ICaL) is reduced in heart disease, both in animal models (4, 13, 29, 
38) and in myocytes from human dilated atria (19, 33). The loss of ICaL has been suggested to 
have a number of sequelae that contribute to the genesis of AF, including (i) changes in 
action potential configuration and the rate-dependence of refractoriness, (ii) abnormalities 
in Ca2+ handling and the triggering of episodes of AF and (iii) hypo-contractility and 
dilatation of the atria (15, 29, 33, 35, 42).  The mechanisms for the downregulation of ICaL 
remain unclear and may be dependent on the underlying disease. For example, both 
spontaneously hypertensive rats and rats with coronary artery ligation-induced myocardial 
infarction show a substrate for atrial fibrillation associated with atrial fibrosis, hypertrophy 
and down-regulation in ICaL (4, 10, 13, 38). However, while the reduced ICaL density in atrial 
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myocytes from spontaneously hypertensive rats compared to currents in normotensive 
Wistar-Kyoto controls has been associated with reduction in expression of the pore-forming 
1c subunit, 1c protein expression was unchanged in rat atrial myocytes from a coronary 
artery ligation model (4, 38).  The reduction in atrial ICaL in coronary artery ligation-induced 
heart failure has been suggested to be due to decreased cyclic AMP-dependent basal 
regulation of L-type Ca2+ channels (4, 19). However, while the cyclic AMP-dependent protein 
kinase, PKA, has also been demonstrated to play an important role in the basal regulation of 
ICaL in ventricular myocytes (7, 8), the constitutive regulation of ventricular ICaL by PKA 
appears to be increased in a coronary artery ligation model of heart failure (9).  In addition, 
the reduction in atrial ICaL in patients with chronic AF has been associated with a reduction in 
calcium-calmodulin-dependent protein kinase II (CaMKII) activity and an increase in protein 
phosphatase activity in AF with no change in the expression of L-type Ca2+ channel subunit 
protein (14).  Changes in the activity of the serine/threonine protein phosphatases, PP1 and 
PP2A, and the regulatory subunit of PP1, inhibitor-1, have been implicated in the pro-
arrhythmic remodeling in AF (25). Thus, the aim of this study was to examine the 
mechanisms underlying the regulation of atrial ICaL in heart failure. The study involved the 
use of the coronary artery ligation model of myocardial infarction-associated heart failure 
reported previously (9, 23).  
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Materials & Methods 
Animals, heart failure and myocyte isolation. All procedures were performed in accordance 
with UK legislation and approved by the University of Bristol Ethics Committee. The study 
was conducted in parallel with another investigation using the same animals to investigate 
ventricular cellular remodeling in heart failure and thereby conformed to the reduction 
component of the 3Rs (9, 23, 41). Heart failure was induced in 10 adult male Wistar rats by 
ligation of the left anterior descending coronary artery (CAL), which results in left ventricular 
hypertrophy and dilatation, and systolic and diastolic dysfunction 16 weeks after surgery (9, 
36). 12 adult male Wistar rats were subject to an equivalent Sham operation (Sham). Left 
atrial myocytes were isolated ~18 weeks after surgery. Operations were performed under 
surgical anesthesia (ketamine 75 mg/kg, medetomidine 0.5 mg/kg, ip) with appropriate 
analgesia (buprenorphine 0.05 mg/kg, sc).  We have previously reported that left ventricular 
ejection fraction was reduced by 50% and left ventricular end diastolic volume was 
increased by more than 100% in CAL as compared with Sham for this group of animals (9). 
Atrial myocytes were isolated using our standard methods (6, 8), following rapid excision of 
the heart under pentobarbitone anesthesia. Isolated myocytes were stored for 2-10 hours 
before use on the day of isolation. 
Whole-cell recording. Whole-cell currents were recorded using the ruptured-patch 
technique, as described previously (6). Myocytes were superfused with Tyrode’s solution 
comprising (mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 2.5 CaCl2, 10 D-glucose and 5 HEPES, pH 7.4 
at 36 oC.  The internal solution comprised (mmol/L): 10 NaCl, 110 KCl, 0.4 MgCl2, 5 D-
glucose, 10 HEPES, 5 BAPTA, 5 K-ATP and 0.5 Tris-GTP, pH 7.3 (KOH).  Currents were low-
pass filtered with a corner frequency of 1 kHz and recorded to the hard drive of a PC at a 
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sampling frequency of 5 kHz. The junction potential was compensated electronically on 
immersion of the pipette tip in the bath solution and no further compensation was applied. 
Whole-cell capacitance transients were compensated electronically.  Series resistances were 
typically between 3 – 8 MΩ in both Sham and CAL myocytes and were not compensated and 
no corrections were made for voltage-drop error.  A square-shaped voltage pulse protocol 
was applied: from a holding potential of -80 mV, 500 ms depolarizing pulses to potentials 
from -40 mV to +50 mV were applied, increasing in 10 mV increments every 5 s. A 50 ms 
pre-pulse to -40 mV was used to inactivate the Na+ current.  The L-type Ca2+ current (ICaL) 
was measured as the difference between the peak inward current and the current at the 
end of the pulse. Although the inward currents recorded under these conditions could be 
completely abolished using 3 μmol/L nifedipine, the contribution of transient outward 
currents may have led to a slight under-estimation in ICaL (13). Current densities were 
calculated as the currents normalized to whole-cell capacitance. Mean ICaL values were 
plotted against the corresponding voltage and the current-voltage relation fitted by a 
modified Boltzmann equation: 
 ,      
 (1) 
where Vm was the membrane potential, Gmax represented the maximum conductance, Vrev 
was the effective reversal potential for the current, Vhalf represents the voltage of half-
maximal activation and k represented a slope factor (6). Fitted parameters are reported 
with the standard error of fitting.  
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Drugs and reagents. All reagents were purchased from Sigma-Aldrich (Poole, UK) unless 
otherwise indicated. Norepinephrine (NE) was dissolved in de-ionized water as a 10 mmol/L 
stock-solution and dissolved to the final concentration in the extracellular solution on the 
day of experiment.  1 μmol/L of NE was used as an effective concentration of the 
physiological agonist of adrenoceptors previously shown to potentiate ICaL maximally and 
that is representative of concentrations achieved at the cardiac sympathetic junction (6, 24). 
Protein kinase A (PKA) was inhibited using 10 μmol/L H-89, a concentration that has been 
shown to inhibit phosphorylation of the cardiac 1c L-type Ca2+ channel subunit (12). In 
some experiments, autocamtide-2-related inhibitory peptide (AIP) was included in the 
pipette solution (5 μmol/L) to inhibit Ca2+-calmodulin-dependent kinase II (CaMKII)  (27).  
Calyculin A (Cal A) was used at a concentration of 100 nmol/L to inhibit the serine/threonine 
protein phosphatases 1 (PP1) and 2A (PP2A) (39).   
Western blotting.  30 μg of protein from cell homogenate samples was run on reducing 4-
15% gradient SDS-PAGE gels and transferred to Immobilon-P membranes.  Membranes were 
probed with anti-Cav1.2 L-type Ca2+ channel 1c subunit (ACC-003; Alomone, Israel), anti-
protein phosphatase 1 (anti-PP1, sc-7482; Santa Cruz Biotechnology Inc., Texas, USA), anti-
protein phosphatase 2A (anti-PP2A, 05-421; Millipore (UK) Ltd, Watford, UK) and anti-
protein phosphatase inhibitor-1 (anti-Inhibitor-1, ab-40877; AbCam, Cambridge, UK). 
Protein bands were visualized and images captured using the appropriate horseradish 
peroxidase-conjugated secondary antibodies, chemiluminescence and a G:BOX Chemi XT4 
imaging system (Syngene).  The densities of the bands were measured using ImageJ 
(https://imagej.nih.gov/ij/) and normalized to the density of the GAPDH band (Sigma-Aldrich 
UK Ltd, Poole, UK).  
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Statistical analysis. Data are presented as the mean ± S.E.M. Statistical analyses were 
performed using Prism (vs5.04, GraphPad Software Inc., USA). Data sets were subject to 
D’Agostino-Pearson omnibus normality test. Sample sizes are provided in the Figure 
Legends as (n numbers of cells/N numbers of animals). Sham versus CAL comparisons in 
single parameters were analyzed using either Mann-Whitney or Student’s unpaired t-test. 
Correlation analysis was performed using Spearman’s rank correlation coefficient. Current-
voltage relations were analyzed by two-way repeated measures (RM) ANOVA with 
Bonferroni post hoc test. Other results were analyzed by one-way RM ANOVA with 
Bonferroni‘s multiple-comparisons test. P≤0.05 was considered as the limit of statistical 
confidence.
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Results 
Single left atrial myocytes were isolated from Sham and CAL rats 18.9±0.45 weeks (n=12) 
and 18.7±0.48 weeks (n=10, P=0.678) following surgery, respectively.  On the day of 
isolation, there was little difference between the two groups in body weight (Sham, 
447.3±9.04 g vs CAL, 491.5±20.1 g; P=0.052) or tibia length (Fig. 1A). However, CAL animals 
showed significantly increased heart weights (HW) and lung weights (LW) relative to tibia 
length (TL; Fig. 1B), indicative of early stage heart failure as demonstrated in our previous 
report using these hearts (9).  In summary, the data indicate early onset heart failure in the 
CAL animals in the present study.  Whole-cell capacitance values of left atrial myocytes 
isolated from CAL hearts were ~1.67 times larger than those from Sham controls, indicating 
considerable cellular hypertrophy of atrial myocytes in heart failure (Fig. 2A). Cell length and 
width were measured in 12 Sham (from 2 hearts) and 12 CAL (from 2 hearts) isolated atrial 
myocytes. While there was no difference in cell length (Sham 103.6±4.1 μm, CAL 113.1±5.8 
μm; P=0.1938), cell width was significantly greater in CAL compared with Sham myocytes 
(Sham 14.5±1.0 μm, CAL 22.0±1.3 μm; P=0.0001). Taken together, these data are consistent 
with the atrial hypertrophy previously reported in coronary artery ligation models of heart 
failure (10, 50).   
Figure 2B shows representative recordings from Sham and CAL myocytes of L-type Ca2+ 
current (ICaL) elicited by depolarizing pulses to +10 mV. Mean ICaL-voltage relations in Sham 
and CAL myocytes are shown in Figure 2C. In both groups of cells, currents were activated 
from voltages of -30 mV, were maximal at around +10 mV and reversed at ~+50 mV, typical 
of cardiac ICaL (Fig. 2C). ICaL-voltage relations were fitted with a modified Boltzmann equation 
(equation 1; see Methods). There were no differences between CAL and Sham myocytes in 
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the voltage of half-maximal activation (Vhalf: Sham -0.72±1.5 mV, CAL: -1.09±2.46 mV), slope 
factor (k: Sham 6.89±0.86 mV, CAL 6.11±1.51 mV) or reversal potential (Vrev: Sham 
48.25±1.38 mV, CAL 49.83±2.94 mV), indicating no significant changes in the voltage-
dependence or ion selectivity of ICaL in heart failure.   However, while the differences 
between CAL and Sham myocytes in mean ICaL did not reach statistical confidence at any 
potential, the fitted maximal conductance was less in CAL than in Sham cells (Gmax: Sham 
17.01±1.51 nS, CAL 11.66±1.92 nS; P=0.0317).  After normalization to cell capacitance, the 
corresponding mean current density-voltage relations (Fig. 2D) show significantly smaller ICaL 
density in CAL myocytes compared to Sham controls at voltages from -10 to +30 mV. The 
maximal conductance density was reduced by more than 50% in CAL compared to Sham 
myocytes (Gmax: Sham 288.4±24.2 pS/pF, CAL 140.6±16.5 pS/pF; P<0.0001).  The correlation 
between ICaL density at +10 mV and cell capacitance in atrial cells from Sham and CAL hearts 
is shown in Figure 2E. In CAL cells, ICaL density was inversely correlated with capacitance (r=-
0.4219, n=31, P=0.0181). Taken together, these data indicate that heart failure through 
coronary artery ligation causes a reduction in whole-cell ICaL density of left atrial myocytes 
that is predominantly due to an increase in cell membrane surface area with minor changes 
in absolute current.   
The reduction in atrial ICaL density by more than 50% caused by CAL-induced heart failure 
was consistent with a previous report in a similar model, in which it was also shown that the 
difference in ICaL density between sham control and heart failure was reduced following β-
adrenoceptor stimulation with isoproterenol (4).  The sympathetic neurotransmitter, NE, 
has previously been shown to potentiate atrial ICaL via β1-adrenoceptors without significant 
contribution from either α1- or β2-adrenoceptors (6). Therefore, the effects of NE on 
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differences in ICaL density between Sham and CAL atrial myocytes were examined. As 
illustrated by the representative current traces in Figure 3, 1 μmol/L NE produced a marked 
increase in ICaL in both Sham and CAL myocytes (Fig. 3A & Fig. 3B).  Notably, although 
statistically significant differences in ICaL density-voltage relations (Fig. 3C) and maximal 
conductance density were evident under control conditions (Gmax: Sham 371.6±65.2 pS/pF, 
CAL 182.0±28.6, P=0.0091), these differences were lost in the presence of NE (Fig. 3D; Gmax: 
Sham 660.6±113.2 pS/pF, CAL 494.3±61.2 pS/pF, P=0.1798). Thus, NE had a greater effect 
on Gmax in CAL (2.72-fold increase) than in Sham (1.78-fold increase) myocytes. In addition, 
Vhalf was negatively shifted by NE in both cell types (Sham control 1.85±2.98 mV to NE -
4.38±2.43 mV, P=0.1434; CAL control 2.93±2.50 mV to NE -5.57±1.66 mV, P=0.0121). 
Overall, these data demonstrate differences in the regulation of the L-type Ca2+ channel 
currents between Sham and CAL cells. To examine whether constitutive phosphorylation of 
LTCC contributed to the differences in ICaL density, cells were superfused with the 
serine/threonine protein phosphatase inhibitor, calyculin A (100 nmol/L) (Fig. 4).  In both 
groups of cells, calyculin A resulted in increased mean current densities at voltages from -20 
mV to +40 mV (Fig. 4). However, the relative increase in maximal conductance was not 
significantly different between the two groups (P=0.4850): in Sham cells, Gmax was increased 
2.75-fold (control 187.2±26.9 pS/pF, calyculin A 514.5±47.4 pS/pF, P<0.0001), whereas in 
CAL cells Gmax was increased 3.34-fold (control 111.3±14.2 pS/pF, calyculin A 371.7±36.1 
pS/pF, P<0.0001). Critically, in contrast to the effect of NE, in the presence of calyculin A, 
Gmax was greater in Sham than in CAL cells (two-way ANOVA, Bonferroni post hoc test, 
P<0.01).  
13 
 
The role of protein kinase A in differences in basal ICaL density between the two groups of 
atrial cells was examined using the PKA inhibitor, H-89 (10 μmol/L) (Fig. 5). Superfusion of 
cells with H-89 had no effect on basal ICaL in either Sham (Fig. 5A) or CAL (Fig. 5B) myocytes, 
although the response to NE (1 μmol/L) was abolished. Further evidence that PKA does not 
contribute to the constitutive regulation of ICaL was obtained in a small series of experiments 
conducted in Sham cells only, in which the increase in ICaL density on superfusion with 100 
nmol/L calyculin A was not abolished by application of the PKA inhibitor, PKI (20 μmol/L), via 
the pipette solution (data not shown). CaMKII has also been suggested to contribute to 
basal ICaL in atrial myocytes (17). Therefore, we examined the effect on basal ICaL of inhibition 
of CaMKII with AIP (5 μmol/L) applied via the intracellular pipette solution in Sham and CAL 
cells (Figure 6). Comparison of the mean current density-voltage relations of the Sham (Fig. 
6A) and CAL (Fig. 6B) myocytes dialyzed with AIP (filled symbols in the figure) with the 
corresponding control data (gray-filled symbols) showed no effect of AIP on basal ICaL in 
either cell type. Moreover, ICaL density was increased by 100 nmol/L calyculin A in both 
Sham and CAL cells dialyzed with AIP. Further evidence that CaMKII played no role in basal 
ICaL came from a small number of experiments in which Sham myocytes were superfused 
with the CaMKII inhibitor, KN-93 (5 μmol/L). Treatment with KN-93 had no effect on mean 
ICaL density at +10 mV in Sham cells (data not shown). Taken together, these data suggest 
that inhibition of CaMKII had no effect on basal ICaL in either Sham or CAL myocytes.   
The expression of proteins for the predominant LTCC pore-forming α1c subunit, Cav1.2, for 
the serine/threonine protein phosphatases, PP1 and PP2A, and for the inhibitory subunit of 
PP1, inhibitor-1, was examined by Western blotting in atrial cell preparations from 3 Sham 
and 3 CAL hearts (Figure 7). There were no significant differences in the total content of 1c 
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subunit relative to GAPDH expression between the two groups of cells. The increase in ICaL 
density on inhibition of protein phosphatase with calyculin A (Fig. 4) indicates a role for 
protein phosphorylation in the basal regulation of L-type Ca2+ channels in both groups of 
cells. However, expression of neither PP1 nor PP2A were changed in heart failure (Fig. 7). 
Moreover, the PKA-dependent inhibitory regulator of PP1, inhibitor-1, reduced expression 
of which in failing ventricles has been suggested to contribute to reduced protein 
phosphorylation (20), was also not different between the two groups of cells.  
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Discussion 
This study clearly demonstrates a reduction in atrial ICaL density in heart failure, due 
predominantly to cellular hypertrophy without significant change in absolute current 
amplitude. However, the total expression of the 1c subunit protein relative to total tissue 
protein was also not changed in heart failure, indicating that the reduction in basal current 
density in heart failure did not involve significant changes in the relative amount of protein 
in hypertrophied cells. It seems likely that a change in L-type Ca2+ channel regulation 
underlay the reduction in ICaL density.  The difference in ICaL density between atrial cells from 
failing and sham hearts was abolished in the presence of NE, which increased the L-type 
Ca2+ current >50% more effectively in CAL cells than in Sham. Moreover, the increase in 
current density produced by inhibition of serine/threonine protein phosphatase activity 
with calyculin A provides evidence of phosphorylation-dependent basal regulation of ICaL in 
both groups of cells.  In these respects, the data resemble those reported by Dinanian et al 
in human atrial myocytes from patients with heart failure (19) and by Boixel et al in a model 
of coronary artery ligation-induced heart failure in rats similar to that used in the present 
study (4) and contrast with studies of chronic hypertension and pressure overload in rats 
that show a reduction in atrial 1c subunit protein expression  (38, 51).  However, contrary 
to the mechanism proposed by Boixel et al. (4), the insensitivity of basal ICaL to H-89 and PKI 
in the present study demonstrated that protein kinase A did not contribute to the 
constitutive regulation of atrial ICaL. This finding differs from the conclusion of Boixel et al 
that the downregulation of atrial ICaL in heart failure was “… caused by changes in basal 
cAMP-dependent regulation of the current …” (4).  A notable difference between that study 
and this is that Boixel et al did not report the effects of inhibition of protein kinase A (4).  
16 
 
Basal ICaL in the present study was also insensitive to AIP and KN-93, demonstrating that, 
unlike human atrial myocytes, CaMKII did not contribute to the constitutive regulation of 
the L-type Ca2+ current (14).  
The present study showed little difference between atrial cells from failing hearts and sham 
controls in the effectiveness of inhibition of the protein phosphatases PP1 and PP2A so that, 
in contrast to previous reports, differences in protein dephosphorylation via these 
phosphatases are unlikely to account for the downregulation of atrial ICaL density in heart 
failure (4, 14).  Consistent with this suggestion, no differences were found in the expression 
of PP1, PP2A or inhibitor-1. The basis for the differences between the study of Boixel et al 
and the present study, in which similar models of heart failure were used, remain unclear 
although it is possible that the results of the present study, in which animals were 
maintained for 18 weeks following coronary artery ligation, represent a more chronic state 
of remodeling than did those of Boixel et al, in which animals were maintained for 3 months 
post-surgery (4, 9, 36, 37).  
The mechanism for the down regulation of atrial ICaL in heart failure remains unclear. A 
number of kinases, including PKC, PKD, PKG and tyrosine kinases, have been reported to 
modulate cardiac ICaL and, in principle, changes in the activity of any of these could 
contribute to the reduction in basal ICaL in heart failure (1, 5, 28). Additionally, calcineurin 
(PP2B) has been suggested to associate with and regulate the L-type Ca2+ channel α1c-
subunit and to contribute to down-regulation of ICaL during atrial remodeling (46, 53).  Atrial 
ICaL is also regulated by NO through complex pathways involving cyclic GMP-dependent PKG, 
cyclic GMP-inhibited phosphodiesterases, and S-nitrosylation of the α1c-subunit (31, 40, 47, 
49). It has been suggested that oxidative stress may contribute to the development of the 
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arrhythmic substrate and down-regulation of ICaL during atrial remodeling and this may 
involve changes in the NO-dependent regulation of L-type Ca2+ channels (11, 21, 43). The 
previously reported changes in atrial intracellular cyclic GMP production together with the 
increased effect of phosphodiesterase inhibition on ICaL are consistent with the proposal that 
changes in NO/cGMP-dependent regulation of L-type Ca2+ channels may underlie both the 
reduced basal current and increased sensitivity to noradrenergic agonism in heart failure (4, 
19). On the other hand, while it has previously been shown that the effect of NE on ICaL is 
almost exclusively mediated via β1-adrenoceptors in atrial myocytes from normal hearts (6), 
the contribution of α1-, β2 and β3-adrenoceptors in heart failure cannot be ruled out (44, 45, 
52).  Thus, future studies using selective adrenoceptor ligands and inhibitors of signaling 
cascades will be important to establish the mechanism underlying the remodeling of atrial 
ICaL regulation in heart failure. 
The present study also adds to evidence that the mechanisms of ICaL regulation differ 
between atrial and ventricular cells (6-8). While both PKA and CaMKII have previously been 
shown to contribute to the basal regulation of ventricular ICaL, particularly at the t-tubule 
membrane, (7-9, 12), basal ICaL in atrial myocytes from either sham control or failing hearts 
in the present study was insensitive to inhibition of PKA or CaMKII. Notably, the absence of 
regulation of basal atrial ICaL by PKA in CAL hearts in the present study contrasts markedly 
with the increased PKA-dependent regulation of basal ICaL at the t-tubule of ventricular 
myocytes reported recently from the same hearts (9).  The action of calyculin A on atrial ICaL 
demonstrates both that the basal regulation of ICaL in rat atrial myocytes depends on 
constitutive phosphorylation by a serine/threonine kinase and that PP1/PP2A phosphatase 
activity contributes to the degree of basal phosphorylation. Thus, the identity of the kinases 
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and phosphatases responsible for the constitutive regulation of atrial ICaL in both normal 
hearts and in heart failure warrants further investigation. 
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Figure Legends 
Fig. 1.  Atrial L-type Ca2+ current density in heart failure. A: Mean tibia length from 12 
Sham and 10 CAL rats. *, P<0.05; Mann-Whitney test.  B: Mean heart weight/tibia length 
and lung weight/tibia length ratios. Sham, filled columns and CAL, open columns. **, 
P<0.01; ****, P<0.001; Mann-Whitney test. 
Fig. 2.  A: Whole-cell capacitances for Sham (n=63/12) and CAL (n=47/10) myocytes.  
****, P<0.0001; Mann-Whitney test. B: Representative whole-cell L-type Ca2+ current 
(ICaL) traces at +10 mV. Sham: black. CAL: gray. C: Mean ICaL-voltage relations for Sham 
(filled circles, n=32/12) and CAL (open circles, n=31/10) myocytes.  D: Mean ICaL density-
voltage relations for Sham (filled circles) and CAL (open circles) myocytes.  The same 
data as shown in C. **, P<0.01; ***, P<0.001; two-way RM ANOVA with Bonferroni post-
test.  Solid lines in C and D represent fits to equation 1. E: Correlation between ICaL 
density at +10 mV in Sham (filled circles, n=32/12) and CAL (open circles, n=31/10) 
myocytes. Atrial ICaL density for the two groups of cells combined was significantly 
correlated (r=-0.4772, n=63/22, P<0.0001).  
Fig. 3.  Effects of norepinephrine on atrial L-type Ca2+ current (ICaL) density. A: 
Representative Ca2+ current traces at +10 mV in an atrial myocyte from a Sham-
operated rat in control conditions and in the presence of 1 μmol/L norepinephrine. B: 
Representative Ca2+ current traces in an atrial myocyte from a CAL rat in control 
conditions and in the presence of 1 μmol/L norepinephrine. Arrows indicate zero 
current level.  C: Mean ICaL density-voltage relations under control conditions from 
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Sham-operated (n=5/3, filled circles) and CAL (n=9/4, open circles). *, P<0.05, Bonferroni 
post-test following two-way RM ANOVA.  D: Mean ICaL density-voltage relations in the 
presence of 1 μmol/L norepinephrine from Sham-operated (n=5/3, open squares) and 
CAL (n=9/4, filled squares).  Data correspond to the control data shown in (C). Note the 
difference in current density scale between panels C and D. Solid lines in panels C and D 
represent fits to equation 1. 
Fig. 4. Atrial L-type Ca2+ currents following phosphatase inhibition. A: (i) Representative 
current traces recorded at +10 mV from a Sham myocyte before and after superfusion 
with 100 nmol/L calyculin A. (ii) ICaL density-voltage relations from Sham myocytes 
(n=6/3) in control (filled circles) and in the presence of 100 nmol/L calyculin A (open 
circles). *, P<0.05; ***, P<0.001; two-way RM ANOVA and Bonferroni post-test.  B: (i) 
Representative current traces recorded at +10 mV from a CAL myocyte before and after 
superfusion with 100 nmol/L calyculin A. (ii) ICaL density-voltage relations from CAL 
myocytes (n=9/3) in control (filled squares) and in the presence of 100 nmol/L calyculin 
A (open squares). ***, P<0.001; two-way ANOVA and Bonferroni post-test.   
Fig. 5. Effect of the protein kinase A inhibitor, H-89. A: (i) Representative Ca2+ current 
traces at +10 mV in an atrial myocyte from a Sham-operated rat in control Tyrode’s, in 
the presence of 10 μmol/L H-89 and in the presence of 10 μmol/L H-89 and 1 μmol/L 
norepinephrine (NE). (ii) Mean ICaL density-voltage relations from Sham myocytes 
(n=8/4) in control (filled circles), in the presence of 10 μmol/L H-89 (gray-filled circles) 
and in the presence of 10 μmol/L H-89 and 1 μmol/L NE (open circles). B: (i) 
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Representative Ca2+ current traces in an atrial myocyte from a CAL rat in control 
Tyrode’s, in the presence of 10 μmol/L H-89 and in the presence of 10 μmol/L H-89 and 
1 μmol/L NE. Right-pointing arrows indicate zero current level. (ii) Mean ICaL density-
voltage relations from CAL myocytes (n=13/4) in control (filled squares), in the presence 
of 10 μmol/L H-89 (gray-filled squares) and in the presence of 10 μmol/L H-89 and 1 
μmol/L NE (open squares). 
Fig. 6. Effect of the Ca2+-calmodulin-dependent protein kinase II inhibitor, AIP.  A: Mean 
ICaL density-voltage relations for Sham myocytes with AIP included in the pipette 
solution (n/N=4/1). Filled circles – AIP-dialyzed cells in control Tyrode’s, open circles – 
AIP-dialyzed cells in the presence of 100 nmol/L calyculin A. B: Mean ICaL density-voltage 
relations for CAL myocytes with AIP included in the pipette solution (n/N=5/1). Filled 
squares – AIP-dialyzed cells in control Tyrode’s, open squares – AIP-dialyzed cells in the 
presence of 100 nmol/L calyculin A. Data from Sham (A) and CAL (B) myocytes under 
control conditions (respectively, n=33/12 and 31/10) are shown as, respectively, gray-
filled circles and gray-filled squares, for comparison.   **, P<0.01; ***, P<0.001; two-way 
RM ANOVA and Bonferroni post-test vs corresponding AIP control.   
Fig. 7. Left atrial expression of the Cav1.2 LTCC 1c subunit and various protein 
phosphatases in heart failure. A: Representative Western blots of LTCC, protein 
phosphatases and GAPDH from Sham and CAL rats.  For each protein, the bands are 
taken from the same gel and have not been manipulated for contrast, color-balance, 
brightness or background. Solid lines demarcate the bands for the target protein and for 
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the GAPDH loading control, which were taken from the same gel. For each protein, the 
molecular weights of the bands are indicated.  B: Mean band intensity expressed 
relative to Sham as 100%. Data are mean ± SEM from 3 Sham and 3 CAL hearts.   
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